Rezidol

Quick links to important sections

Rezidol

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rezidol

Property Description
Active ingredient Oxaliplatin
Form Solution for infusion
Pharmacological class Antineoplastic Agent (Chemotherapy)
Common use Cancer treatment
Origin Synthetic (Platinum-based compound)

What Type of Chemotherapy is Rezidol?

Rezidol is a specialized, prescription-only medicine used in the treatment of cancer, classifying it as an antineoplastic agent (chemotherapy). Its active component is Oxaliplatin, a synthetic compound that places it within the unique family of platinum analogs. This categorization is clinically recognized due to the central role the platinum atom plays in disrupting cancer cell function.

The effectiveness of Oxaliplatin in hindering cell division confirms its status as a foundational drug in cancer care. As an integral component of many oncology treatment plans, its general purpose is to interfere with the rapid growth cycles of malignant cells, thereby controlling or slowing the progression of the disease.

What is the Composition and Form of Rezidol?

The composition of Rezidol is centered entirely on its single active ingredient, Oxaliplatin, and it is supplied as a sterile solution for infusion. This preparation is administered intravenously (IV) into a vein, which ensures the drug bypasses the digestive system and is quickly distributed throughout the body. This method of administration is crucial for achieving the necessary systemic reach to target cancer cells wherever they may be. Because of its potency and specific delivery requirement, Rezidol requires careful preparation and precise administration by a healthcare professional in a clinical setting.

What side effects are possible with Rezidol?

Possible side effects and safety information for Rezidol

This section outlines the officially documented safety profile of Rezidol, based strictly on the structure and content mandated by government regulatory agencies. The information presented reflects the categorization of risks and limitations required for the medicine’s official labeling.

Adverse Reactions Scope

The most common adverse reactions identified in clinical trials are categorized by frequency (e.g., Very Common, Common) and by the affected System-Organ Class (e.g., Gastrointestinal, Nervous System). This classification provides a comprehensive view of expected side effects.

Regulatory documentation also defines Serious Adverse Reactions—those considered life-threatening, requiring hospitalization, or resulting in significant disability—which are highlighted in mandatory sections like Warnings and Precautions.

Safety Restrictions and Monitoring

Contraindications are conditions, such as known hypersensitivity to the drug, that strictly prohibit the use of Rezidol due to unacceptable risk. Additionally, the label details specific Safety-Related Restrictions or Limitations concerning use with other drugs or in patients with certain pre-existing medical conditions.

Regulatory authorities may also require Population-Specific Safety Considerations if safety data demonstrates a unique risk profile for pediatric, geriatric, or renally/hepatically impaired patient groups. Post-Marketing Safety Surveillance ensures that the drug's official risk assessment is continuously updated with real-world data.

Official Safety Summary

The structure of Rezidol's safety information, mandated by regulatory bodies, systematically classifies all risks from the most frequently reported side effects to the critical, less frequent serious events. This architecture provides a standardized, tiered understanding of the medicine’s risk profile and the necessary precautions for its use.

Overdose and Emergency Response

Overdose Manifestations and Required Emergency Actions

Overdose with Rezidol (Oxaliplatin) may present with signs of severe systemic toxicity, which are documented in official regulatory labeling. These manifestations can include signs of cardiovascular changes, such as slowed heartbeat or chest pain, and respiratory distress, often presenting as slowed breathing, wheezing, or shortness of breath. Other documented signs include severe gastrointestinal findings like vomiting and diarrhea, as well as specific sensory effects, such as numbness or tingling in the extremities or a tightening of the throat.

When to Seek Immediate Medical Help

The occurrence of certain life-threatening outcomes, as defined in regulatory guidance, requires an immediate call to emergency services (e.g., 911). This action is mandated if an individual has collapsed, experiences a seizure (convulsion), or has severe trouble breathing. Contacting a poison control helpline is also advised for assistance.

Official Management Strategy

Official prescribing information confirms that no specific antidote is known for Rezidol overdose. Consequently, management is officially stated as consisting of symptomatic and supportive treatment. Additionally, if there is a suspected administration error resulting in the leakage of the drug outside the vein (extravasation), drug administration must be stopped immediately, and local symptomatic measures should be initiated as described in the regulatory text.

Therapeutic Uses of Rezidol

What Rezidol Treats: Main Uses and Benefits

The principal purpose of Rezidol (Oxaliplatin) is to provide systemic control over aggressive malignant disease, primarily colorectal cancer. Its therapeutic benefit may contribute to supporting patients in two critical areas: slowing the active progression of established tumors and helping to manage the risk of disease recurrence after surgery. The medication is commonly used to treat advanced cancer of the colon or rectum, and is applied to help manage the risk of the disease spreading in people who have had surgery to remove the tumor, often alongside other agents to achieve optimal results.

It is used to address conditions involving high uncontrolled malignant cell proliferation in clinical scenarios such as advanced (metastatic) colorectal cancer and Stage III colon cancer following surgical resection. This agent is commonly used within combination chemotherapy regimens to support a comprehensive therapeutic effect against the malignant disease.

“This agent is considered relevant for supporting the patient during difficult phases of the illness and stabilizing the disease burden in later stages.”


Controlling Advanced Colorectal Cancer

This domain covers the use of the medicine when the cancer is advanced or has spread to distant organs (metastatic disease). The core therapeutic benefit helps to slow the rate of malignant cell proliferation and supports the control of established tumors. This application is considered relevant for supporting the patient during difficult phases of the illness and stabilizing the disease burden in later stages of the illness.

Quick Fact: Support for Conditions Involving Malignant Cell Growth Rezidol may assist with maintaining functional stability by supporting the control of malignant cell growth, which helps ease the overall symptom load when applied as part of a therapeutic regimen.


Managing Recurrence Risk After Surgery (Adjuvant Use)

Rezidol is commonly applied as adjuvant therapy (follow-up treatment) after a patient has undergone the complete surgical removal of a high-risk tumor, such as Stage III colon cancer. The primary benefit here is that it may assist with addressing any groups of cancer cells that may remain in the body, which may help reduce the risk of the disease returning and supports the patient in maintaining long-term functional stability.


Supporting Combination Cancer Regimens

This agent is commonly used when applied as a foundational component within combination chemotherapy regimens. This supports a comprehensive effect against the malignant disease, supports tumor response, and is relevant for easing the overall symptom load when applied as part of a therapeutic regimen.

Regulatory References

  1. Oxaliplatin Injection: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Rezidol?

The population eligibility for Rezidol (Oxaliplatin) is strictly defined by regulatory authorities and is determined by a patient’s medical history, age, and organ function prior to treatment.

Eligibility Status Patient/Condition Restriction Basis
Contraindicated Known hypersensitivity to oxaliplatin or other platinum compounds Platinum allergy
Contraindicated Severely impaired renal function (Creatinine Clearance < 30 mL/min) Organ function
Contraindicated Pre-existing peripheral sensory neuropathy with functional impairment Neurological status
Contraindicated Females who are breastfeeding Physiological state
Not Recommended Pediatric population (children and adolescents) Efficacy/Safety not established
Conditional Use Mild to moderate renal impairment Requires close monitoring

The medicine is indicated for use only in the adult population. Use in children and adolescents is not recommended because its safety and effectiveness have not been established by regulatory bodies. Treatment is also formally contraindicated if the patient presents with low baseline blood counts (myelosuppression) prior to the first course. Furthermore, use is not recommended during pregnancy due to the risk of fetal harm. Males and females of reproductive potential are advised to use effective contraception.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Rezidol (Oxaliplatin) documents specific interactions categorized by chemical incompatibility, pharmacodynamic risk, and pharmacokinetic effects.

Incompatibility and Timing Rules Rezidol must not be mixed or administered with alkaline medications, solutions containing chlorides, or through injection equipment containing aluminum. Due to these incompatibilities, the Rezidol infusion must always precede the administration of fluoropyrimidines such as 5-Fluorouracil, as required by regulatory labeling.

Interactions Affecting Exposure Pharmacokinetic analysis shows that Oxaliplatin does not inhibit or metabolize Cytochrome P450 isoenzymes, meaning P450-mediated interactions are not anticipated. However, certain high-dose regimens have been documented to cause an increase in the plasma concentration of co-administered 5-Fluorouracil. Furthermore, co-administration with potentially nephrotoxic compounds may decrease the clearance of platinum species, and the exposure of unbound platinum is increased in patients with severe renal impairment.

Additive Risk Interactions Co-administration with other medicinal products known to prolong the QT interval requires careful monitoring due to the potential for an additive effect on cardiac repolarization. Similarly, increased frequency of monitoring is required when co-administered with oral anticoagulants due to the reported risk of hemorrhage and altered International Normalized Ratio (INR). Caution is also advised when combining with other neurotoxic drugs due to the potential for additive nerve toxicity.

Mechanism of Action

How Rezidol Works: Mechanism of Action

Rezidol (Oxaliplatin) exerts its physiological activity through two distinct, yet complementary, mechanistic domains: genetic disruption resulting in cytotoxicity, and transient alteration of peripheral nerve function.


Core Mechanism: Direct DNA Cross-Linking and Cytotoxicity

This domain describes the primary molecular interaction and the resulting cascade that dictates the drug's primary mechanism of action. The drug's molecule undergoes non-enzymatic activation and covalently binds to the DNA within rapidly multiplying cells, specifically forming cross-links that physically prevent the cell from copying its genetic material (replication). This severe genetic damage triggers the cellular surveillance system, initiating programmed cell death (apoptosis), resulting in cellular cytotoxicity.


Secondary Mechanism: Modulation of Sensory Neuron Excitability

The second domain involves a separate, non-cytotoxic interaction with peripheral neurons. The drug's structure transiently modulates voltage-gated sodium channels embedded in nerve cell membranes, altering their kinetics. This distinct mechanism temporarily changes the electrical excitability and signal transmission properties of sensory nerve fibers, which results in a transient alteration of peripheral neuron kinetics.

Dosage and Administration Information

Administration Guidelines for Rezidol

This section describes the procedures for administering Rezidol.

Rezidol is intended for oral administration and is available in multiple dosage forms, including tablets, an oral solution, and orally disintegrating tablets (ODT).


Dosing and Schedule

Patient Population Recommended Starting Dose Titration Rule
Adults (Standard) 2 mg once daily Increase in 1–2 mg increments, no sooner than every 24 hours.
Pediatric/Adolescent (13–17) 0.5 mg once daily Increase gradually, with a target dose of 3 mg daily.
Severe Hepatic/Renal Impairment 0.5 mg twice daily Increases should occur at intervals of at least one week.

The daily dosage is often divided for administration twice daily, though once-daily dosing is also an approved regimen. The medicine may be taken with or without food.


Preparation and Special Conditions

  • Oral Solution: The liquid formulation can be mixed with common beverages like water, coffee, orange juice, or low-fat milk. The solution must not be mixed with cola or tea.
  • Orally Disintegrating Tablets (ODT): The ODT should be placed on the tongue immediately after opening the blister packaging and swallowed with or without liquid.
  • Interruption of Therapy: If Rezidol treatment is stopped for more than one week, the patient must restart the full initial dosing and titration schedule upon resumption.

Recent Clinical Evidence

Research Evidence for Rezidol (Oxaliplatin)


Evidence for Use in Advanced or Metastatic Colorectal Cancer

The research base for Rezidol (Oxaliplatin) in advanced or metastatic colorectal cancer is structured around large Randomized Controlled Trials (RCTs). These are studies where participants are randomly assigned to different treatment groups, often comparing an Oxaliplatin-containing combination against other chemotherapy regimens or placebo. Researchers applied these studies examining patient-reported experiences and outcomes related to systemic or functional imbalance. The studies primarily involved adult patients whose cancer had spread to distant organs.

Studies examined how treatment regimens incorporating Rezidol compared against other approaches by monitoring several clinical metrics, including Objective Response Rate (a measure of tumor size changes), Time to Tumor Progression, and Overall Survival. Findings describe patterns observed in the studies related to Time to Tumor Progression. The evidence base is predominantly structured around studies where Rezidol was used in combination with other chemotherapy agents. The research structure limits the ability to isolate the effects of Oxaliplatin alone.


Evidence for Adjuvant Treatment of Stage III Colon Cancer

For patients who have had surgery to remove Stage III colon cancer, Rezidol has been evaluated in major, multi-center Large-scale, Multi-Center Randomized Controlled Trials (RCTs). These studies followed participants for many years to understand the observed outcomes of receiving an Oxaliplatin-based regimen following the tumor removal.

Studies monitored key outcomes reflecting long-term disease status, primarily focusing on Disease-Free Survival (DFS) and Overall Survival (OS). These outcomes reflect the incidence of disease recurrence and the long-term status of the disease during the observation period. Research continues to explore the effects of different durations of this post-surgical treatment, with some studies comparing standard versus shorter durations. Evidence quality varies across studies when examining outcomes for specific subgroups, such as older adults (ge 70 years).

Key Studies & References

  1. Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial

Frequently Asked Questions (FAQ)

Common questions about Rezidol (FAQ)


Q: What is the main reason doctors prescribe Rezidol?

The official indications for Rezidol are primarily limited to the treatment of certain stages of colorectal cancer. Specifically, it is used for the adjuvant treatment of Stage III colon cancer and the management of advanced colorectal cancer. This information is detailed in the official prescribing documents.


Q: If I miss a dose of Rezidol, what is the generally accepted advice?

If a patient misses a scheduled administration or appointment, official patient information advises immediately contacting the healthcare provider. Because Rezidol is a specialized infusion administered in a clinical setting, your healthcare provider will determine the necessary instructions to manage your treatment schedule.


Q: Can Rezidol be taken with common over-the-counter medications like Tylenol?

Official drug labeling does not typically list every common over-the-counter medication. However, regulatory warnings emphasize caution when Rezidol is co-administered with any other products that have nephrotoxic (potentially damaging to the kidneys) or neurotoxic (potentially damaging to the nerves) effects.


Q: Does taking Rezidol mean I can't drive?

The official prescribing information advises that side effects of Rezidol, such as dizziness, nausea, and vomiting, may temporarily impair a patient's ability to drive or operate machinery. It is important for patients to monitor how they react to the medicine before engaging in activities that require full attention.


Q: Why is Rezidol often prescribed for conditions that seem unrelated?

The official regulatory documents for Rezidol strictly limit its approved use to the treatment of colorectal cancer. The content of the patient FAQ must be focused only on these approved uses, as determined by regulatory agencies.


Q: What if Rezidol doesn't seem to be working after a few days?

The effectiveness of Rezidol is typically evaluated over a course of treatment, not within a few days. For advanced cancer, the medicine is generally continued until disease progression or the development of unacceptable toxicity, both of which are assessed by a healthcare professional.


Q: Does Rezidol interact with birth control pills?

While regulatory information does not detail a specific drug interaction between Rezidol and oral contraceptives, official labeling strongly mandates that females of reproductive potential use effective contraception during treatment and for a period afterward. This requirement is in place due to the risk of fetal harm.


Q: Where can I find the official patient information leaflet for Rezidol?

Official patient information, including drug labeling and leaflets, is publicly available through government health sources. You can find this material on reliable sites such as the National Institutes of Health (NIH) MedlinePlus and the Food and Drug Administration (FDA) DailyMed service.


Q: Why is my doctor asking me to get lab work done while taking Rezidol?

Official labeling requires regular monitoring through lab work to check for several risks associated with Rezidol. This is necessary to watch for potential issues like severe neutropenia (low white blood cell counts), liver toxicity, and potential cardiovascular effects.


Q: Are there any common supplements that interact with Rezidol?

The official labeling requires caution when Rezidol is co-administered with products that have neurotoxic or nephrotoxic effects. Patients are generally advised to discuss all supplements they are taking with their healthcare team, as some products may fall into these categories.


Q: Is Rezidol available as a generic drug?

Yes, the medicine's active component, Oxaliplatin, is available in generic form. This is the same active ingredient found in the original brand-name product, which was marketed under the name Eloxatin.


Q: If I have a mild side effect, should I stop Rezidol?

The regulatory approach to managing side effects is based on their severity. Only serious or persistent adverse events (often categorized as Grade 3/4) typically warrant physician-directed discontinuation or a dose adjustment, not usually mild symptoms.


Q: What are the signs that Rezidol might be working for me?

Efficacy is not usually measured by signs that a patient can perceive immediately. Instead, healthcare professionals assess effectiveness using clinical metrics like Objective Response Rate and Time to Tumor Progression, which monitor disease status over time.


Q: Are there different brand names for the same medicine, Rezidol?

Yes, the active ingredient in Rezidol is Oxaliplatin. This medicine has been marketed by different companies under the original brand name Eloxatin, in addition to being available as a generic.


Q: What if I take too much Rezidol accidentally?

Regulatory documents advise that an overdose of Rezidol may result in severe, potentially life-threatening side effects. These can include nervous system problems, extreme nausea and vomiting, and serious blood cell disorders.


Q: Why do some people say Rezidol makes them feel dizzy?

Dizziness is a documented adverse reaction that may be associated with certain cardiovascular risks, specifically the risk of QT prolongation (changes in heart rhythm). Your healthcare provider monitors for this possibility during treatment.


Q: Is it common to feel tired when starting Rezidol?

Yes, the official clinical trial results list fatigue (tiredness) as a very common side effect. This means it was reported by a significant number of patients during the studies.


Q: How long do most people stay on Rezidol?

The duration of treatment is determined by the specific condition being managed. For adjuvant treatment, the therapy is typically recommended for a total of 6 months. For advanced disease, treatment usually continues until the disease progresses or unacceptable toxicity develops.


Q: Is Rezidol safe for older adults (seniors)?

Official regulatory data indicates that no specific dose adaptation is generally required for the geriatric population (patients over 65). studies found no increase in severe toxicities when the medicine was used in this population.


Q: What is the purpose of the different strengths Rezidol comes in?

The medicine is supplied in different strengths and forms to allow for precise, individualized dosing for each patient. This ensures that the correct milligram amount, which is often calculated based on a patient's body surface area, is administered.


Q: Can Rezidol affect sleep patterns?

Yes, official regulatory documents list insomnia (difficulty sleeping) as a reported common side effect. Any significant changes in sleep are typically discussed with the patient's healthcare provider.


Q: Are there any known foods or drinks that should be avoided while taking Rezidol?

Official patient information advises against ingesting fresh or cold food or beverages during and immediately following the administration of Rezidol. This precaution is necessary to prevent a neurological side effect called laryngo-pharyngeal dysaesthesia.


Q: What happens if I stop taking Rezidol suddenly?

The regulatory labeling focuses on the risks that require therapy to be discontinued by a physician, such as persistent severe neuropathy or specific blood disorders. Official guidelines emphasize that therapy should not be interrupted without the oversight of a healthcare professional.


Q: Are the side effects of Rezidol permanent?

While certain effects, particularly sensory peripheral neuropathy (nerve damage), have been documented to be persistent, other side effects are often managed by a dose reduction or discontinuation of the drug. Questions regarding the potential for long-term effects are best addressed by a specialist.


Q: Can Rezidol cause weight changes?

Yes, official documents list anorexia (loss of appetite) as a common adverse reaction. This lack of appetite, alongside other gastrointestinal effects, can potentially lead to weight changes.


Q: What are the most serious side effects listed for Rezidol?

Regulatory documents highlight critical risks in the Warnings and Precautions section. These serious effects include potentially fatal severe allergic reactions (anaphylaxis), severe nerve problems, and serious effects on blood counts and the cardiovascular system.


Q: Is Rezidol safe for people with a history of heart issues?

The official label advises that low mineral levels, specifically hypokalemia or hypomagnesemia, should be corrected prior to starting the medicine. This is due to the documented risk of heart rhythm changes, known as QT prolongation.


Q: Is it normal to feel a mild headache after starting Rezidol?

Headache is listed in regulatory documents as a common side effect affecting the nervous system. Severe or persistent headaches, like any concerning symptom, are typically reported to a healthcare professional.


Q: What is the risk of an allergic reaction to Rezidol?

Serious and potentially fatal allergic reactions (hypersensitivity) can occur. Official data from clinical trials shows this occurred in approximately 2% to 3% of colon cancer patients.


Q: How do I know if I'm eligible to use Rezidol?

Eligibility for Rezidol is strictly defined by the medicine's approved uses (indications) and official conditions, called contraindications, that strictly prohibit its use. These contraindications include severe kidney problems or pre-existing nerve damage with functional impairment.


Q: What does the FDA / EMA say about Rezidol's safety profile?

The FDA, EMA, and other agencies require the labeling to include a Boxed Warning for serious risks such as anaphylaxis. They also mandate specific Warnings and Precautions related to nerve damage, blood disorders, and potential cardiovascular issues to ensure patients and physicians are fully aware of the risk profile.


Q: Can Rezidol worsen pre-existing conditions?

Yes, the official label lists existing conditions that may be worsened by the medicine and which strictly prohibit its use. Examples include pre-existing peripheral sensory neuropathy (with functional impairment) and low baseline blood counts (myelosuppression).


Q: Does Rezidol affect blood pressure?

Yes, regulatory documents list hypertension (high blood pressure) as a common side effect classified under vascular disorders. This is one of the many parameters that may be monitored by your healthcare team during treatment.


Q: Is Rezidol only for short-term use?

The official duration of use varies based on the condition being treated. For adjuvant treatment, the course is set for a total of 6 months, while for advanced disease, treatment continues until the cancer progresses or the patient experiences unacceptable toxicity.

How should Rezidol be stored and disposed of?

How to Store and Dispose of Rezidol?

The storage and disposal of Rezidol (Oxaliplatin) must adhere to strict regulatory standards due to its classification as a cytotoxic drug.

Storage Requirements:

The concentrated solution must be stored at Controlled Room Temperature (20 C to 25 C) and must not be frozen. It is mandatory to keep the vial in the original outer carton to protect the solution from light.

Stability and Handling:

Once the solution is diluted for infusion, it has limited stability. It must be used or discarded if stored for more than 6 hours at room temperature or 24 hours under refrigeration. Personnel must follow special procedures during handling, and administration equipment containing aluminum must not be used.

Disposal Rules:

Any unused or expired product must be discarded immediately and destroyed according to established hospital procedures for hazardous/cytotoxic waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rezidol found in:

A-Z Index: